BiotechnologyBiologics CDMO Market: 41% of Growth to Originate from North America, Mammalian Segment to be Significant for Revenue Generation – Technavio

The biologics CDMO market is set to grow by USD 8.65 billion from 2021 to 2026 as per the latest market forecast report by Technavio. The report projects the market to progress at a CAGR of  12.20%. 41% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for biologics CDMO market in North America. Market growth in this region will be faster than the growth of the market in ROW. The rising patient awareness about the benefits of the use of biologics will facilitate the biologics CDMO market growth in North America over the forecast period.

Biologics CDMO Market: Segmentation Analysis

The market research report segments the biologics CDMO market by Type (Mammalian, Microbial, and Cell therapy services) and Geography (North America, Europe, Asia, and ROW).

• Revenue Generating Segment – The biologics CDMO market share growth by the mammalian segment will be significant for revenue generation. Mammalian cell culture is the process of growing animal cells in vitro in a flask or dish. There are four types of mammalian cells, namely fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are found within the blood, and the rest three are found in tissue. This segment accounts for the major share of the market in focus in 2021 due to the rising use of mammalian cells in the treatment of many diseases.

To know about the market contribution of each segment – Grab a Free sample report

Biologics CDMO Market: Major Driver

• The availability of cost-efficient resources in emerging markets is one of the key drivers supporting the biologics CDMO market growth.
•  For instance, India, is one of the most preferred countries for CDMOs, has more than 100 US FDA-approved manufacturing facilities, and the number of such facilities is increasing in the country. The strong presence of companies such as LUPIN and Zydus Cadila is increasing the share of the biologics CDMO market in the pharmaceutical industry in the country. It is estimated that India contributes approximately one-third of the global biologics CDMO revenue. Therefore, the global biologics CDMO market is expected to grow strongly during the forecast period.

Biologics CDMO Market: Major Trend

• The advent of big data is a major trend supporting the biologics CDMO market growth.
•  Considering that drug development is a long process with complex data handling, the growing use of analytical tools for clinical data synthesis is helping companies quicken the drug development process. For instance, big data is a strategy that has gained popularity in the healthcare industry, including pharmaceuticals, to help with the decision-making for R&D. The use of data analytics is effective for the identification of new potential drug candidates, the identification and monitoring of side effects, and others, which can be avoided at the early stages. Such applications will drive market growth during the forecast period.

To know about the other drivers & trends along with challenges – Request a Free Sample

 The competitive scenario provided in the Biologics CDMO Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don’t wait, Make a strategic approach & boost your business goals with our Biologics CDMO Market Forecast Report –  Buy Now!

Related Reports:

• The celiac diseases drugs market share is expected to increase by USD 601.57 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 16.95%.
• The narcolepsy drugs market share is expected to increase to USD 1.60 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 9.1%.